Detalles de la búsqueda
1.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36990608
2.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
; 381(2): 121-131, 2019 07 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31157964
3.
Cost-effectiveness analysis of metformin with enzalutamide in the metastatic castrate-resistant prostate cancer setting.
Can J Urol
; 26(6): 10045-10053, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31860422
4.
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Cancer
; 122(3): 411-9, 2016 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26540173
5.
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
Cancer
; 119(16): 2999-3006, 2013 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23696129
6.
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
Lancet Oncol
; 13(12): 1210-7, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23142059
7.
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey.
Curr Oncol
; 30(7): 6166-6176, 2023 06 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37504318
8.
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Eur J Cancer
; 171: 124-132, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35717820
9.
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
J Clin Oncol
; 40(8): 837-846, 2022 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34928708
10.
Defining cisplatin eligibility in patients with muscle-invasive bladder cancer.
Nat Rev Urol
; 18(2): 104-114, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33432181
11.
Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Eur Urol
; 80(6): 693-700, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34399998
12.
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
Eur Urol
; 80(3): 275-279, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34030924
13.
Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials.
Am J Clin Oncol
; 43(8): 559-566, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32398404
14.
Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection.
Can Urol Assoc J
; 14(8): E373-E382, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32209217
15.
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial.
JAMA Oncol
; 6(11): 1751-1758, 2020 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32940628
16.
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol Oncol
; 2(6): 643-648, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31411994
17.
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.
Eur J Cancer
; 108: 69-77, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30648632
18.
Predictive Biomarkers in Muscle Invasive Bladder Cancer: Are We There Yet?
Eur Urol
; 83(4): 318-319, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36155158
19.
The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study.
Bladder Cancer
; 4(2): 185-194, 2018 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-29732389
20.
Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies.
Clin Genitourin Cancer
; 2017 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28993132